Lifestyle and pharmacological approaches to weight loss: Efficacy and safety

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 11 SUPPL. 1, 2008, Pages

  Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMFEPRAMONE; BENZETHONIUM CHLORIDE; BENZPHETAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; FENFLURAMINE; KETOCONAZOLE; MELFIAL; METFORMIN; MONOAMINE OXIDASE INHIBITOR; OBEZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE RESIN; PHENTRIDOL; PLACEBO; PRELU 2; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SIMVASTATIN; TETRAHYDROLIPSTATIN; TETRAMINE; TOPIRAMATE; UNCLASSIFIED DRUG; X TROZINE; ZONISAMIDE;

AEROBIC EXERCISE; AORTA VALVE REGURGITATION; AREA UNDER THE CURVE; ASTHENIA; BLOOD PRESSURE; CALORIC INTAKE; CLINICAL TRIAL; CONSTIPATION; DIETARY INTAKE; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENERGY BALANCE; FEEDING BEHAVIOR; GASTROINTESTINAL DISEASE; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; LOW CARBOHYDRATE DIET; LOW FAT DIET; MENTAL DISEASE; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN DIET; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

EID: 55849122229     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1294     Document Type: Review

References (68)

1. World Health Organization 2000 Obesity: preventing and managing the global epidemic. Report of a WHO consultation. Tech Rep Ser 894. Geneva: World Health Organization; i-xii, 1-253
2. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults 1998 Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 6:51S-63S
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM 2006 Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555
4. Bray GA 2007 The metabolic syndrome and obesity. Totowa, NJ: Humana Press
5. Keys A, Brozek J, Henschel A, Mickelsen O, Taylor HL 1950 The biology of human starvation. Vols. 1 and 2. Minneapolis, MN: University of Minnesota Press
6. Kinsell LW, Gunning B, Michaels GD, Richardson J, Cox SE, Lemon C 1964 Calories do count. Metabolism 13:195-204
7. Bray GA 2008 Good calories, bad calories by Gary Taubes; New York: AA Knopf. Obes Rev 9:251-263
8. Freedman MR, King J, Kennedy E 2001 Popular diets: a scientific review. Obes Res 9(Suppl 1):1S-40S
9. Foster GD, Wadden TA, Peterson FJ, Letizia KA, Bartlett SJ, Connill MJ 1992 A controlled comparison of three very-low calorie diets: effects on body weight, body composition and symptoms. Am J Clin Nutr 55:811-817
10. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, Leibel RL 2002 Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 87:2391-2394
11. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM 2004 Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 8:iii-iv, 1-182
12. Douketis JD, Macie C, Thabane L, Williamson DF 2005 Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 29:1153-1167
13. Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G 2000 Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 8:399-402
14. Pirozzo S, Summerbell C, Cameron C, Glasziou P 2003 Should we recommend low-fat diets for obesity? Obes Rev [Erratum (2003) 4:185] 4:83-90
15. Howard BV, Manson JE, Stefanick ML, Beresford SA, Frank G, Jones B, Rodabough RJ, Snetselaar L, Thomson C, Tinker L, Vitolins M, Prentice R 2006 Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA 295:39-49
16. Astrup A, Grunwald GK, Melanson EL, Saris WH, Hill JO 2000 The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes Relat Metab Disord 24:1545-1552
17. Ludwig DS 2002 The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 287:2414-2423
18. Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS 2004 Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA 292:2482-2490
19. Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS 2007 Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA [Erratum (2007) 298:627] 297:2092-2102
20. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S 2003 A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348:2082-2090
21. Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams M, Gracely EJ, Samaha FF 2004 The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 140:778-785
22. Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA 2003 A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab 88:1617-1623
23. Skov AR, Toubro S, Rønn B, Holm L, Astrup A 1999 Randomized trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity. Int J Obes Relat Metab Disord 23:528-536
24. Due A, Toubro S, Skov AR, Astrup A 2004 Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int J Obes Relat Metab Disord 28:1283-1290
25. Westerterp-Plantenga MS, Lejeune MP, Nijs I, van Ooijen M, Kovacs EM 2004 High protein intake sustains weight maintenance after body weight loss in humans. Int J Obes Relat Metab Disord 28:57-64
26. Paddon-Jones D, Westman E, Mattes RD, Wolfe RR, Astrup A, Westerterp-Plantenga M 2008 Protein, weight management, and satiety. Am J Clin Nutr 87:1558S-1561S
27. 2005 Rating the diets from Atkins to Dr. Sears Zone. Consum Rep 70:18-22
28. Atkins RC 2002 Dr. Atkins's new diet revolution. New York: Avon
29. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ 1998 Intensive lifestyle changes for reversal of coronary heart disease. JAMA [Erratum (1999) 281:1380] 280:2001-2007
30. Agatson A 2003 The South Beach Diet. London: Headline Book Publishing
31. Rolls BJ, Barnett RA 2000 Volumetrics: feel full on fewer calories. New York: Harper Collins
32. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ 2005 Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293:43-53
33. Gardner CD, Kiazand A, Alhassan S, Kim S, Stafford RS, Balise RR, Kraemer HC, King AC 2007 Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA [Erratum (2007) 298:178] 297:969-977
34. Alhassan S, Kim S, Bersamin A, King AC, Gardner CD 2008 Dietary adherence and weight loss success among overweight women: results from the A TO Z weight loss study. Int J Obes (Lond) 32:985-991
35. Wing RR, Phelan S 2005 Long-term weight loss maintenance. Am J Clin Nutr 82(Suppl 1):222S-225S
36. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
37. Wing RR, Hamman RF, Bray GA, Delahanty L, Edelstein SL, Hill JO, Horton ES, Hoskin MA, Kriska A, Lachin J, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner JG, Venditti B, Wylie-Rosett J; Diabetes Prevention Program Research Group 2004 Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res 12:1426-1434
38. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thorbaben J, Wing RR, Yanovski SZ 2007 Reduction in weight and cardiovascular disease (CVD) risk factors in individuals with type 2 diabetes: one year results of Look AHEAD Trial. Diabetes Care 30:1374-1383
39. Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Serdula M, Brown TJ, Schmid CH, Lau J 2004 Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 117:762-774
40. Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk EM 2007 Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med 14741-14750
41. Church TS Earnest CP, Skinner JS, Blair SN 2007 Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA 297:2081-2091
42. Saris WH, Blair SN, van Baak MA, Eaton SB, Davies PS, Di Pietro L, Fogelholm M, Rissanen A, Schoeller D, Swinburn B, Tremblay A, Westerterp KR, Wyatt H 2003 How much physical activity is enough to prevent unhealthy weight gain? Outcome of the IASO 1st Stock Conference and consensus statement. Obes Rev 4:101-114
43. Wood PD, Stefanick ML, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, Superko HR, Fortmann SP, Albers JJ, Vranizan KM, Ellsworth NM, Terry RB, Haskell WL 1988 Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 319:1173-1179
44. Dattilo AM, Kris-Etherton PM 1992 Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56:320-328
45. Jakicic JM, Winters C, Lang W, Wing RR 1999 Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial. JAMA 282:1554-1560
46. Schoeller DA, Shay K, Kushner RF 1997 How much physical activity is needed to minimize weight gain in previously obese women? Am J Clin Nutr 66:551-556
47. Jeffery RW, Wing RR, Sherwood NE, Tate DF 2003 Physical activity and weight loss: does prescribing higher physical activity goals improve outcome? Am J Clin Nutr 78:684-689
48. Bray GA, Greenway FL 2007 Pharmacological treatment of the overweight patient. Pharmacol Rev 59:151-184
49. Berthoud HR 2002 Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 26:393-428
50. Lam DD, Pryzdzial MJ, Ridley SH, Yeo GS, Rochford JJ, O'Rahilly S, Heisler LK 2008 Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 40:1323-1328
51. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R 2006 The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100
52. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB 1999 Sibutramine produces dose-related weight loss. Obes Res 7:189-198
53. Rucker D, Padwal R, Li SK, Curioni C, Lau DC 2007 Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335:1194-1199
54. Wirth A, Krause J 2001 Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286:1331-1339
55. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, Renz CL, Pirner MA, Walch JK, Jasinsky O, Hewkin AC, Blakesley VA; Sibutramine Adolescent Study Group 2006 Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 145:81-90
56. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ 2005 Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353:2111-2120
57. Kim SH, Lee YM, Jee SH, Nam CM 2003 Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 11:1116-1123
58. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L 2004 XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care [Erratum (2004) 27:856] 27:155-161
59. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J 2005 Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA [Erratum (2005) 294:1491] 293:2873-2883
60. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM 2000 Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 8:431-437
61. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group 2005 Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet [Erratum (2005) 366:370] 365:1389-1397
62. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134
63. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group 2006 Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA [Erratum (2006) 295:1252] 295:761-775
64. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group 2006 Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet [Erratum (2006) 368:1650] 368:1660-1672
65. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators 2008 Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299:1547-1560
66. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup 2007 A Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet [Erratum (2008) 371:558] 370:1706-1713
67. Weintraub M 1992 Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 51:581-585
68. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV 1997 Valvular heart disease associated with fenfluramine- phentermine. N Engl J Med 337:581-588